Literature DB >> 3759961

Progesterone receptor synthesis and degradation in MCF-7 human breast cancer cells as studied by dense amino acid incorporation. Evidence for a non-hormone binding receptor precursor.

A Mullick, B S Katzenellenbogen.   

Abstract

We have used the technique of density labeling of proteins by biosynthetic incorporation of 2H, 13C, 15N (dense) amino acids to study the synthesis and degradation rates of the progesterone receptor in MCF-7 human breast cancer cells. In cells grown in the absence of progestin, sucrose gradient shift analyses reveal that it takes 17 h for the normal density progesterone receptor levels to be reduced to half the initial value, whereas in the presence of 10 nM of the synthetic progestin [3H]R5020, the receptor turns over more rapidly, such that the normal density R5020-occupied progesterone receptor complexes are reduced to half in 12 h. The accelerated progesterone receptor turnover in the presence of [3H]R5020 reflects increased turnover rates of both the A (Mr-85,000) and B (Mr-115,000) subunits, as determined by sodium dodecyl sulfate gel analyses of dense and light receptors photoaffinity labeled with [3H]R5020. In both control and progestin-exposed cells, the time course of progesterone receptor turnover shows a lag of approximately 6 h after dense (15N, 13C, 2H) amino acid exposure, before dense hormone binding receptor species are seen and before normal density progestin binding activity starts decreasing. Since our evaluations of progesterone receptor depend upon its binding of radiolabeled ligand ([3H]R5020), this lag in the density shift kinetics would be consistent with the presence of a non-hormone binding biosynthetic precursor, from which the hormone-binding form of progesterone receptor is derived. A kinetic model is used to analyze the lag-decay profiles and to determine the rate constants for progesterone receptor synthesis, activation to the hormone-binding form, and degradation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3759961

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Ligand-dependent degradation of SRC-1 is pivotal for progesterone receptor transcriptional activity.

Authors:  Larbi Amazit; Audrey Roseau; Junaid A Khan; Anne Chauchereau; Rakesh K Tyagi; Hugues Loosfelt; Philippe Leclerc; Marc Lombès; Anne Guiochon-Mantel
Journal:  Mol Endocrinol       Date:  2011-01-27

Review 2.  Mechanisms and significance of nuclear receptor auto- and cross-regulation.

Authors:  Pia Bagamasbad; Robert J Denver
Journal:  Gen Comp Endocrinol       Date:  2010-03-23       Impact factor: 2.822

3.  Peroxisome proliferator-activated receptor gamma activation inhibits progesterone-stimulated human MUC1 expression.

Authors:  Peng Wang; Neeraja Dharmaraj; Melissa J Brayman; Daniel D Carson
Journal:  Mol Endocrinol       Date:  2010-05-19

4.  Mifepristone-inducible transgene expression in neural progenitor cells in vitro and in vivo.

Authors:  B E Hjelm; C Grunseich; G Gowing; P Avalos; J Tian; B C Shelley; M Mooney; K Narwani; Y Shi; C N Svendsen; J H Wolfe; K H Fischbeck; T M Pierson
Journal:  Gene Ther       Date:  2016-02-10       Impact factor: 5.250

5.  Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.

Authors:  Leticia Labriola; Mariana Salatino; Cecilia J Proietti; Adalí Pecci; Omar A Coso; Alberto R Kornblihtt; Eduardo H Charreau; Patricia V Elizalde
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

6.  Nuclear tristetraprolin acts as a corepressor of multiple steroid nuclear receptors in breast cancer cells.

Authors:  Tonatiuh Barrios-García; Vania Gómez-Romero; Ángeles Tecalco-Cruz; Viviana Valadéz-Graham; Alfonso León-Del-Río
Journal:  Mol Genet Metab Rep       Date:  2016-03-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.